OSE Immunotherapeutics Statistics
Total Valuation
OSE Immunotherapeutics has a market cap or net worth of EUR 172.72 million. The enterprise value is 199.85 million.
Market Cap | 172.72M |
Enterprise Value | 199.85M |
Important Dates
The next estimated earnings date is Friday, September 27, 2024.
Earnings Date | Sep 27, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
OSE Immunotherapeutics has 21.75 million shares outstanding.
Shares Outstanding | 21.75M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 25.58% |
Owned by Institutions (%) | 1.14% |
Float | 15.40M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 2.34 |
PS Ratio | 69.75 |
PB Ratio | 7.46 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -8.69 |
EV / Sales | 89.74 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -10.10 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 199.35.
Current Ratio | 1.62 |
Quick Ratio | 1.40 |
Debt / Equity | 199.35 |
Debt / EBITDA | n/a |
Debt / FCF | -2.32 |
Interest Coverage | -10.47 |
Financial Efficiency
Return on equity (ROE) is -82.70% and return on invested capital (ROIC) is -19.65%.
Return on Equity (ROE) | -82.70% |
Return on Assets (ROA) | -16.53% |
Return on Capital (ROIC) | -19.65% |
Revenue Per Employee | 40,491 |
Profits Per Employee | -418,236 |
Employee Count | 55 |
Asset Turnover | 0.03 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +185.61% in the last 52 weeks. The beta is 0.91, so OSE Immunotherapeutics's price volatility has been similar to the market average.
Beta (5Y) | 0.91 |
52-Week Price Change | +185.61% |
50-Day Moving Average | 6.90 |
200-Day Moving Average | 5.51 |
Relative Strength Index (RSI) | 64.26 |
Average Volume (20 Days) | 121,448 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OSE Immunotherapeutics had revenue of EUR 2.23 million and -23.00 million in losses. Loss per share was -1.18.
Revenue | 2.23M |
Gross Profit | 2.23M |
Operating Income | -22.99M |
Pretax Income | -23.22M |
Net Income | -23.00M |
EBITDA | -22.66M |
EBIT | -22.99M |
Loss Per Share | -1.18 |
Balance Sheet
The company has 18.67 million in cash and 45.80 million in debt, giving a net cash position of -27.13 million or -1.25 per share.
Cash & Cash Equivalents | 18.67M |
Total Debt | 45.80M |
Net Cash | -27.13M |
Net Cash Per Share | -1.25 |
Equity (Book Value) | 22.98M |
Book Value Per Share | 1.06 |
Working Capital | 11.68M |
Cash Flow
In the last 12 months, operating cash flow was -19.76 million and capital expenditures -16,000, giving a free cash flow of -19.78 million.
Operating Cash Flow | -19.76M |
Capital Expenditures | -16,000 |
Free Cash Flow | -19.78M |
FCF Per Share | -0.91 |
Margins
Gross Margin | 100.00% |
Operating Margin | -1,032.15% |
Pretax Margin | -1,042.75% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -888.19% |
Dividends & Yields
OSE Immunotherapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -14.86% |
FCF Yield | -11.45% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |